Zacks Investment Research
21 Jul 2026, 14:55 UTC · 5h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Wall Street analysts have a mean price target of $34.63 for Arcutis Biotherapeutics (ARQT), implying a 25.8% upside from its last close of $27.53. — Positive analyst consensus and a significant gap between current price and targets typically attract buyer interest.
+0.40There is strong analyst agreement regarding Arcutis Biotherapeutics' potential to report earnings that exceed previous predictions. — Positive earnings revisions are a strong fundamental indicator of potential stock price appreciation.
+0.30The standard deviation among the eight short-term price targets for ARQT is low at $0.92, indicating high analyst convergence. — Tight clustering of analyst targets reduces perceived uncertainty but has less direct impact than the targets themselves.
+0.10Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The stock shows significant upside potential based on analyst price targets and positive earnings estimate revisions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
5h ago
